Bayer Pulls Remaining Trasylol Supply
This article was originally published in The Pink Sheet Daily
Executive Summary
The anti-bleeding agent has been under an FDA-requested marketing suspension since last November.
You may also be interested in...
TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.
TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer
Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.
The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
Deal expands TMC’s pipeline, with an eye on the antifibrinolytic market left empty by the Trasylol withdrawal.